Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Awarded miR-122-Related Patent Coverage in Australia

Premium

Regulus Therapeutics said this week that that Australian Patent Office has recently granted certain claims in a company-controlled patent family covering the use of microRNA-122 in treating hepatitis C.

The intellectual property stems from the so-called Sarnow patent estate, which is owned by Stanford University and exclusively licensed to Regulus in the US, Europe, and Australia.

Regulus is developing a miR-122-targeting drug for the treatment of HCV in collaboration with GlaxoSmithKline (GSN 2/25/2010).